Baillie Gifford & CO Summit Therapeutics Inc. Call Options Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SMMT
# of Institutions
192Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$432 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$194 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$140 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$96.3 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$61.4 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.56B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...